Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:


		Three Months Ended March 31,
(In thousands)		2025				2024
Royalties - RELVAR/BREO		$	50,890			$	52,138
Royalties - ANORO			10,373				9,733
Total royalties			61,263				61,871
Less: amortization of capitalized fees paid			(3,456	)			(3,456	)
Total net royalty revenue		$	57,807			$	58,415

Schedule of net product sales

Total net product sales was as follows:


		Three Months Ended March 31,
(In thousands)		2025				2024
GIAPREZA®		$	18,273			$	12,081
XERAVA®			4,223				4,768
XACDURO®			7,783				2,235
Total net product sales		$	30,279			$	19,084